Compare
Aprea Therapeutics, Inc. vs Anixa Biosciences Inc vs Synlogic, Inc. vs Aditxt, Inc.
| Latest fiscal year | Aprea Therapeutics, Inc. APRE | Anixa Biosciences Inc ANIX | Synlogic, Inc. SYBX | Aditxt, Inc. ADTX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-10-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $0 | $3.2K |
| Revenue growth (YoY) | n/a | n/a | -100.0% | -97.6% |
| Gross margin | n/a | n/a | n/a | 8.4% |
| Operating margin | n/a | n/a | n/a | n/m |
| Net margin | n/a | n/a | n/a | n/m |
| Net income | -$12.60M | -$10.93M | -$1.00M | -$43.10M |
| EPS (Diluted) | -$1.93 | -$0.34 | -$0.08 | -$1153.83 |
| Operating cash flow | -$12.89M | -$7.17M | -$4.36M | -$25.69M |
| Free cash flow | n/a | n/a | -$4.36M | -$25.70M |
| Cash & equivalents | $14.60M | $1.24M | $14.67M | n/a |
| Total assets | $15.93M | $16.08M | $15.45M | $16.52M |
| Total liabilities | n/a | $2.13M | n/a | $12.56M |
| Shareholders' equity | $12.44M | $15.16M | $11.86M | $5.61M |
| Return on year-end equity | -101.3% | -72.1% | -8.5% | -768.3% |
| Shares outstanding | 8.19M | 33.01M | 11.70M | 411.5K |
Revenue, most recent five fiscal years
| Fiscal year | Aprea Therapeutics, Inc. | Anixa Biosciences Inc | Synlogic, Inc. | Aditxt, Inc. |
|---|---|---|---|---|
| Latest | n/a | $210.0K Ended 2024-10-31 | $0 Ended 2025-12-31 | $3.2K Ended 2025-12-31 |
| 1 year earlier | n/a | $210.0K Ended 2023-10-31 | $8.0K Ended 2024-12-31 | $134.0K Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | $3.37M Ended 2023-12-31 | $645.2K Ended 2023-12-31 |
| 3 years earlier | n/a | $512.0K Ended 2021-10-31 | $1.18M Ended 2022-12-31 | $933.7K Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $1.75M Ended 2021-12-31 | $105.0K Ended 2021-12-31 |